Selection of antimicrobial agents in periodontal therapy
- PMID: 12366863
- DOI: 10.1034/j.1600-0765.2002.00004.x
Selection of antimicrobial agents in periodontal therapy
Abstract
Background: The recognition over the past 3 decades of microbial specificity in periodontitis has afforded dental practitioners the ability to prevent and treat the disease with a variety of antimicrobial drugs. These include systemic antibiotics, topical antibiotics and topical antiseptics.
Results: Systemic antibiotic therapy can be essential in eliminating pathogenic bacteria that invade gingival tissue and in helping control periodontal pathogens residing in various domains of the mouth from where they may translocate to periodontal sites. Frequently used periodontal combination antibiotic therapies are metronidazole-amoxicillin (250-375 mg of each 3 x daily for 8 days) and metronidazole-ciprofloxacin (500 mg of each 2 x daily for 8 days). Microbiological analysis helps determine the optimal antibiotic therapy and effectiveness of treatment. Topical antibiotics that are commercially available as controlled release devices suffer from several potential problems, including insufficient spectrum of antimicrobial activity in some periodontal polymicrobial infections, risks of producing an antibiotic resistant microbiota, and high acquisition costs. Topical antiseptics of relevance in periodontal treatment include 10% povidone-iodine placed subgingivally by a syringe for 5 min, and 0.1% sodium hypochlorite solution applied subgingivally by patients using an irrigation device.
Clinical implications: The present paper recommends periodontal treatment that includes a battery of professionally and patient-administered antimicrobial agents (properly prescribed systemic antibiotics, povidone-iodine and sodium hypochlorite subgingival irrigants, and chlorhexidine mouthrinse). Available chemotherapeutics can provide effective, safe, practical and affordable means of controlling subgingival colonization of periodontal pathogens and various types of periodontal disease.
Similar articles
-
Periodontal antimicrobials--finding the right solutions.Int Dent J. 2005 Feb;55(1):3-12. doi: 10.1111/j.1875-595x.2005.tb00025.x. Int Dent J. 2005. PMID: 15747646
-
The use of metronidazole and amoxicillin in the treatment of advanced periodontal disease. A prospective, controlled clinical trial.J Clin Periodontol. 1998 May;25(5):354-62. doi: 10.1111/j.1600-051x.1998.tb02455.x. J Clin Periodontol. 1998. PMID: 9650870 Clinical Trial.
-
The ins and outs of periodontal antimicrobial therapy.J Calif Dent Assoc. 2002 Apr;30(4):297-305. J Calif Dent Assoc. 2002. PMID: 12005374 Review.
-
Nonsurgical periodontal therapy.Periodontol 2000. 2001;25:77-88. doi: 10.1034/j.1600-0757.2001.22250106.x. Periodontol 2000. 2001. PMID: 11155183 Review.
-
Low-cost periodontal therapy.Periodontol 2000. 2012 Oct;60(1):110-37. doi: 10.1111/j.1600-0757.2011.00429.x. Periodontol 2000. 2012. PMID: 22909110
Cited by
-
Full-mouth ultrasonic debridement associated with povidone iodine rinsing in GAgP treatment: a randomised clinical trial.Clin Oral Investig. 2016 Jan;20(1):141-50. doi: 10.1007/s00784-015-1471-y. Epub 2015 Apr 16. Clin Oral Investig. 2016. PMID: 25875425 Clinical Trial.
-
Comparison of the efficacy of subgingival irrigation with 2% povidone-iodine and tetracycline HCl in subjects with chronic moderate periodontitis: A clinico microbiological study.Dent Res J (Isfahan). 2016 Mar-Apr;13(2):98-109. Dent Res J (Isfahan). 2016. PMID: 27076823 Free PMC article.
-
Effects of Chlorhexidine and Povidone-Iodine on the SARS-CoV-2 Load: A Systematic Review and Meta-analysis.Eur J Dent. 2023 Jul;17(3):587-601. doi: 10.1055/s-0042-1753470. Epub 2022 Sep 8. Eur J Dent. 2023. PMID: 36075270 Free PMC article.
-
Resolvin D2 Induces Resolution of Periapical Inflammation and Promotes Healing of Periapical Lesions in Rat Periapical Periodontitis.Front Immunol. 2019 Feb 26;10:307. doi: 10.3389/fimmu.2019.00307. eCollection 2019. Front Immunol. 2019. PMID: 30863409 Free PMC article.
-
Antimicrobial Activity of Xibornol and a Xibornol-Based Formulation Against Gram-Positive Pathogens of the Respiratory Tract.Adv Exp Med Biol. 2022;1369:101-106. doi: 10.1007/5584_2021_664. Adv Exp Med Biol. 2022. PMID: 34387849
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous